Development of an Effective Neutralizing Antibody Assay for SARS-CoV-2 Diagnosis
Zhigang Liu,Jiahui Liang,Hangzhan Hu,Mengli Wu,Jingjing Ma,Ziwei Ma,Jianing Ji,Hengyi Chen,Xiaoquan Li,Zhizeng Wang,Yang Luo
DOI: https://doi.org/10.2147/IJN.S408921
IF: 7.033
2023-06-12
International Journal of Nanomedicine
Abstract:Zhigang Liu, 1, &ast Jiahui Liang, 1, &ast Hangzhan Hu, 1, &ast Mengli Wu, 1, &ast Jingjing Ma, 1 Ziwei Ma, 1 Jianing Ji, 1 Hengyi Chen, 2 Xiaoquan Li, 1 Zhizeng Wang, 1, 2 Yang Luo 2, 3 1 Joint National Laboratory for Antibody Drug Engineering, Clinical Laboratory of the First Affiliated Hospital, School of Medicine, Henan University, Kaifeng, 475004, People's Republic of China; 2 Center of Smart Laboratory and Molecular Medicine, Jiangjin Hospital, School of Medicine, Chongqing University, Chongqing, 400044, People's Republic of China; 3 College of Life Science and Laboratory Medicine, Kunming Medical University, Kunming, 650500, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhizeng Wang, Joint National Laboratory for Antibody Drug Engineering, Clinical Laboratory of the First Affiliated Hospital, School of Medicine, Henan University, Kaifeng, 475004, People's Republic of China, Tel +86 15093628687, Email Yang Luo, Center of Smart Laboratory and Molecular Medicine, Jiangjin Hospital, School of Medicine, Chongqing University, Chongqing, 400044, People's Republic of China, Tel +86 13594088001, Email .cn Introduction: Neutralizing antibodies (NAbs) are essential for preventing reinfection with SARS-CoV-2 and the recurrence of COVID-19; nonetheless, the formation of NAbs following vaccination and infection remains enigmatic due to the lack of a practical and effective NAb assay in routine laboratory settings. In this study, we developed a convenient lateral flow assay for the rapid and precise measurement of serum NAb levels within 20 minutes. Methods: Receptor-binding domain-fragment crystallizable (RBD-Fc) and angiotensin-converting enzyme 2-histidine tag (ACE2-His) were expressed by the eukaryotic expression systems of Spodoptera frugiperda clone 9 and human embryonic kidney 293T, respectively. Then, colloidal gold was synthesized and conjugated with ACE2. After optimizing various operating parameters, an NAb lateral flow assay was constructed. Subsequently, its detection limit, specificity, and stability were systematically evaluated, and clinical samples were analyzed to validate its clinical feasibility. Results: RBD-Fc and ACE2-His were obtained with 94.01% and 90.05% purity, respectively. The synthesized colloidal gold had a uniform distribution with an average diameter of 24.15 ± 2.56 nm. With a detection limit of 2 μg/mL, the proposed assay demonstrated a sensitivity of 97.80% and a specificity of 100% in 684 uninfected clinical samples. By evaluating 356 specimens from infected individuals, we observed that the overall concordance rate between the proposed assay and conventional enzyme-linked immunosorbent assay was 95.22%, and we noticed that 16.57% (59/356) of individuals still did not produce NAbs after infection (both by ELISA and the proposed assay). All the above tests by this assay can obtain results within 20 minutes by the naked eye without any additional instruments or equipment. Conclusion: The proposed assay can expediently and reliably detect anti-SARS-CoV-2 NAbs after infection, and the results provide valuable data to facilitate effective prevention and control of SARS-CoV-2. Clinical trial registration: Serum and blood samples were used under approval from the Biomedical Research Ethics Subcommittee of Henan University, and the clinical trial registration number was HUSOM-2022-052. We confirm that this study complies with the Declaration of Helsinki. Keywords: clinical detection, colloidal gold, neutralizing antibody, point-of-care test, SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide because of its high infectiousness and worrying mutagenicity. 1,2 Therefore, NAbs are key to preventing reinfection and the recurrence of infection by diverse microorganisms, and more than 13 billion SARS-CoV-2 vaccine doses have been injected worldwide to effectively combat the virus as of February 17, 2023. 3 In most cases, plasma cells produce NAbs as a result of vaccine-induced humoral immunity, and individuals can be protected from reinfection when NAb levels reach the needed concentration. 4,5 According to a recent study, the level of anti-SARS-CoV-2 NAbs varies widely and declines precipitously within a few months; 4 as a result, booster vaccine doses have been administered in most nations to increase the level of anti-SARS-CoV-2 NAbs. 6 Many teams exploit virus, 7 fluorescence, 8,9 enzymology,< -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology